In females, an increase in estrus cycle length was observed at all dose levels, together with a small reduction in numbers of corpora lutea at 0.03 mg/kg/day
Both omeprazole and esomeprazole inhibit CYP2C19, leading to: Reduced formation of active clopidogrel metabolite Decreased antiplatelet efficacy Increased risk of thrombotic events (MI, stroke, stent thrombosis) Clinical takeaway: When gastric protection is required in patients on clopidogrel, consider safer alternatives such as: Pantoprazole Rabeprazole This simple switch can significantly improve therapeutic outcomes and patient safety
And also, I know that even the WHO these days are thinking about trying to develop GLP-1s for solving the problem of the global obesity
Supplementation strategy Specific supplements meaningfully improve the tirzepatide experience
Who cannot use Semaglutide GLP-1 injections
The first month is a dose escalation phase, which means appetite suppression is only partially active